|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.422 - 0.455|
|52 Week Range||0.250 - 0.890|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.08|
Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a developer of innovative materials as hemostatic and wound care devices, today announced the pricing of registered direct offering of 9.1 million units, each unit consisting of a share of the Company’s common stock, and a Series G Warrant (“Series G Warrant”) to purchase 0.75 of a share of our common stock for the combined purchase price of $0.50 per unit. The Series G Warrants have an exercise price of $0.70 per share and are exercisable for a period of five years. Actual results could differ from those projected in any forward-looking statements due to numerous factors.
Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, provided an update today in which it announced that in the recently initiated skin sensitization study of AC5TM Topical Gel (AC5), two-thirds of the applications of AC5 in the repeat dosing induction phase have occurred and the study remains on schedule. The study, designed as a single-center, prospective, clinical investigation, in approximately 50 healthy subjects, comprises an induction phase separated from a challenge phase by a rest period. During the induction phase, AC5 on a patch is applied to each subject’s back three times weekly over 21 days for a total of 9 applications.
Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin sensitization study and that applications of the Company’s AC5™ Topical Gel are underway for all subjects. Terrence W. Norchi, MD, President and CEO of Arch, said, "This study is an important component of our plans to address the request by the Food and Drug Administration (FDA or “the Agency”). The Agency had requested further evidence beyond that which was previously supplied to support that AC5 does not cause sensitization in humans.
FRAMINGHAM, Mass., May 15, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8 th LD Micro Invitational. ...
Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it will initiate the previously disclosed study designed to address the Food and Drug Administration’s (FDA or "the agency") comments on Arch’s previous 510(k) submission for its AC5TM Topical Gel. The agency has provided feedback via the pre-submission process and has indicated that the proposed study design is acceptable to support the Company’s future marketing application. At present, the Company believes that there are no other material items to address with the agency.
OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for ...
Arch Therapeutics, Inc. , developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company made a 510 submission to the U.S. Food and Drug Administration for ...